The present invention relates to a granular pharmaceutical composition obtained by coating a nucleus with: (1) a layer containing a material having a damp-proofing function, and (2) a drug layer containing linaclotide, a pharmaceutically acceptable salt, or a hydrate thereof, and (3) a layer containing a material having a damp-proofing function. Also, the present invention relates to a method for manufacturing the granular pharmaceutical composition obtained by coating the nucleus with (1) the layer containing the material having a damp-proofing function, (2) the drug layer containing the linaclotide, the pharmaceutically acceptable salt, or the hydrate thereof, and (3) the layer containing the material having a damp-proofing function.

The present disclosure provides pharmaceutical compositions of niclosamide that may be administered orally. These compositions may allow the achievement of a therapeutically effective dose of niclosamide while preventing crystallization in the stomach which reduces bioavailability. These compositions may be used to treat one or more diseases or disorders such as a viral infection or cancer.

Dry powder compositions comprising biologically active antibodies or antibody fragments thereof are provided herein. In some aspects, the present disclosure includes methods of manufacturing these compositions and methods of using them in pulmonary administration or applying them to a tissue surface through a medical dry powder blower/sprayer/insufflator.

A microparticle is described comprising an antigen and a costimulatory component derived from an antigen presenting cell. The microparticle may be used for stimulating T cells ex vivo, followed by administration to a subject, e.g., as part of a personalized, customized therapeutic treatment of cancer or a tumor, an autoimmune disease or an allergic reaction, hypersensitivity reaction, an infection or infectious disease, an injury or other damage, a transplant or other surgical site, or a blood clot. It may also be used for the controlled release of a cytokine for the regulation of immunity in general and for other therapeutic uses. Methods of treating a disease or medical condition in a subject by exposing leukocytes from the subject to the microparticle, then reinfusing the leukocytes into the subject are provided. Methods of preparing an activated cytotoxic T cell population specific for an antigen are also provided.

Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

Compositions in homogenised powder form consisting of hydroxypropyl methylcellulose particles, and at least one chemical signalling agent in particle form, and optionally a biologically active agent, wherein the homogenised powder comprises particles having a mean particle diameter of ≥20 μm to ≤500 μmm uses and kits therefor.

Methods and monodisperse glass microsphere composites comprising a porous wall hollow-glass microsphere; a cargo of a therapeutic is loaded inside of the porous wall hollow-glass microsphere; and a first shell fully encapsulating the porous wall hollow-glass microsphere and capping pores in the walls, retaining the cargo inside of the porous wall hollow-glass microsphere.

The present disclosure relates to a process for preparing pitolisant hydrochloride of Formula-(I) and solid-state forms thereof. ##STR00001##

The present invention relates to a process to prepare solid pharmaceutical forms comprising a quantity of mesalazine comprised between 75 and 95%, i.e. between 1000 and 1600 mg of drug per dosage unit. Furthermore, the present invention relates to a granulate and/or tablets obtained/obtainable with the process according to the invention, preferably coated to allow the con -trolled release of the drug. Finally, the present invention relates to the use of the granulate and/or the tablets as a medicament, prefer -ably for the treatment of chronic inflammatory pathologies that preferably affect the intestinal tract.

A method for preparing nicotine-containing agglomerates includes introducing a solid particulate into a fluid bed granulator, and introducing a binder solution into the fluid bed granulator such that the binder solution contacts the solid particulate. The solid particulate and/or binder solution may be introduced into the fluid bed granulator in parts, concurrently or in series. The binder solution includes a binder material and a solvent, which may include water. Introducing the binder solution into the fluid bed granulator may include spraying the binder solution into a fluid bed of the fluid bed granulator during circulation of the fluid bed and materials therein, such as the solid particulate. The fluid bed may further include a filler material and/or an additive. The filler material and/or the additive may be introduced into the fluid bed granulator prior to, concurrently with, or subsequent to the addition of the solid particulate and/or binder solution.